Taku Asano

Showing 1-20 of 29 articles

Coronary interventions

Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials

Asano T, Ono M, Dai Z, Saito A, Kanie T, Takaoka Y, Mizuno A, Yoneoka D, Komiyama N

October 5, 2021 | 10.4244/EIJ-D-21-00192

Coronary interventions

Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial

Miyazaki Y, Muramatsu T, Asano T, Katagiri Y, Sotomi Y, Nakatani S, Takahashi K, Kogame N, Higuchi Y, Ishikawa M, Kyono H, Yano M, Ozaki Y, Serruys P, Okamura T, Onuma Y

March 19, 2021 | 10.4244/EIJ-D-18-00902

Coronary interventions

Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6- and 24-month results of the DESSOLVE III OCT study

Milewski K, Takahashi K, Asano T, Katagiri Y, Hochul M, Buszman P, Tomaniak M, Gorycki B, Zurakowski A, Janas A, Mlodziankowski A, Kachel M, Wykrzykowska J, Wijns W, de Winter R, Buszman P, Onuma Y, Serruys P

February 19, 2021 | 10.4244/EIJ-D-18-01201

Coronary interventions

BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial

Chang C, Kogame N, Asano T, von Birgelen C, Sabaté M, Onuma Y, Serruys P

December 4, 2020 | 10.4244/EIJ-D-19-00566

Coronary interventions

Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study

Asano T, Kogame N, Onuma Y, Modolo R, Chichareon P, Lefèvre T, Legutko J, Digne F, Morel M, Serruys P, Gil R

October 23, 2020 | 10.4244/EIJ-D-19-00361

Coronary interventions

Preclinical evaluation of a thin-strut bioresorbable scaffold (ArterioSorb): acute-phase invasive imaging assessment and hemodynamic implication.

Katagiri Y, Torii R, Takahashi K, Tenekecioglu E, Asano T, Chichareon P, Tomaniak M, Piek J, Wykrzykowska J, Bullett N, Ahmed N, Al-Lamee K, Al-Lamee R, Leclerc G, Kitslaar P, Dijkstra J, Reiber J, Poon E, Bourantas C, Gijsen F, Serruys P, Onuma Y

June 12, 2020 | 10.4244/EIJ-D-18-01190

Coronary interventions

Clinical outcomes of bioabsorbable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: two-year follow-up of the DESSOLVE III trial

Katagiri Y, Onuma Y, Lurz P, Buszman P, Piek J, Wykrzykowska J, Asano T, Kogame N, Takahashi K, Chang C, de Winter R, Serruys P, Wijns W

February 7, 2020 | 10.4244/EIJ-D-18-00944

Coronary interventions

Acute and long-term relocation of minimal lumen area after bioresorbable scaffold or metallic stent implantation

Katagiri Y, Serruys P, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Katsikis A, Piek J, Wykrzykowska J, Chevalier B, Mintz G, Stone G, Onuma Y

September 20, 2019 | 10.4244/EIJ-D-18-00422

Coronary interventions

Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial

Chichareon P, Onuma Y, van Klaveren D, Modolo R, Kogame N, Takahashi K, Chang C, Tomaniak M, Asano T, Katagiri Y, van Geuns R, Bolognese L, Tumscitz C, Vrolix M, Petrov I, Garg S, Naber C, Sabaté M, Iqbal J, Wykrzykowska J, Piek J, Spitzer E, Jüni P, Hamm C, Steg P, Valgimigli M, Vranckx P, Windecker S, Serruys P

August 9, 2019 | 10.4244/EIJ-D-19-00184

Coronary interventions

A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial

Modolo R, Chichareon P, Kogame N, Asano T, Chang C, de Winter R, Kaul U, Zaman A, Spitzer E, Takahashi K, Katagiri Y, Soliman O, Van Es G-A, Morel M, Onuma Y, Serruys P

July 19, 2019 | 10.4244/EIJ-D-18-00499

Coronary interventions

Early strut protrusion and late neointima thickness in the Absorb bioresorbable scaffold: a serial wall shear stress analysis up to five years

Tenekecioglu E, Torii R, Katagiri Y, Asano T, Modolo R, Miyazaki Y, Chichareon P, Poon E, Gijsen F, Thondapu V, van Klaveren D, Jonker H, Ooi A, Barlis P, Collet C, Onuma Y, Bourantas C, Serruys P

July 19, 2019 | 10.4244/EIJ-D-18-00381

Coronary interventions

How does the failure of Absorb apply to the other bioresorbable scaffolds? An expert review of first-in-man and pivotal trials

Katagiri Y, Serruys P, Asano T, Miyazaki Y, Chichareon P, Modolo R, Takahashi K, Kogame N, Wykrzykowska J, Piek J, Onuma Y

May 20, 2019 | 10.4244/EIJ-D-18-00607

Coronary interventions

A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial

Asano T, Jin Q, Katagiri Y, Kogame N, Takahashi K, Chang C, Chichareon P, Wang C, Shi B, Su X, Fu G, Wu Y, Zhou X, Yuan Z, Wykrzykowska J, Piek J, Serruys P, Onuma Y, Chen Y

December 20, 2018 | 10.4244/EIJ-D-18-00461

Coronary interventions

Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

Katagiri Y, Onuma Y, Asano T, Iñiguez A, Okkels Jensen L, Cequier A, Hofma S, Christiansen E, Suttorp M, Brugaletta S, Räber L, Sabaté M, Windecker S, Serruys P, Räber L, Sabaté M, Serruys P

December 7, 2018 | 10.4244/EIJ-D-18-00839

Coronary interventions

Optical coherence tomography substudy of a prospective multicentre randomised post-market trial to assess the safety and effectiveness of the Firehawk cobalt-chromium coronary stent (rapamycin target-eluting) system for the treatment of atherosclerotic lesions: TARGET All Comers

Baumbach A, Lansky A, Onuma Y, Asano T, Johnson T, Anderson R, Kiemeneij F, Zeng M, van Royen N, Slagboom T, Vlachojannis G, Serruys P, Wijns W

November 20, 2018 | 10.4244/EIJ-D-18-00226

Coronary interventions

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek J, Wykrzykowska J, Abizaid A, Ormiston J, Chevalier B, Serruys P

October 12, 2018 | 10.4244/EIJ-D-18-00301

Reply to the letter to the editor “Stenosis severity indices cannot reflect lumen loss in stent trials”

Asano T, Onuma Y, Reiber J, Serruys P

September 20, 2018 | 10.4244/EIJ-D-17-01073R

STEMI

Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial

Sotomi Y, Onuma Y, Liu S, Asano T, Eggermont J, Katagiri Y, Cavalcante R, de Winter R, Wykrzykowska J, Brugaletta S, Räber L, Sabaté M, Windecker S, Dijkstra J, Serruys P

August 24, 2018 | 10.4244/EIJ-D-17-00884

Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy

Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, Amoroso G, Aminian A, Brugaletta S, Vrolix M, Hernandez-Antolín R, van de Harst P, Iñiguez A, Janssens L, Smits P, Wykrzykowska J, Ribeiro V, Pereira H, da Silva P, Piek J, Reiber J, von Birgelen C, Sabaté M, Onuma Y, Serruys P

August 3, 2018 | 10.4244/EIJ-D-17-00461

Coronary interventions

Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial

Tijssen RY, Kraak R, Elias J, van Dongen I, Kalkman D, Nassif M, Sotomi Y, Asano T, Katagiri Y, Collet C, Piek J, Henriques J, de Winter R, Tijssen J, Onuma Y, Serruys P, Wykrzykowska J

July 20, 2018 | 10.4244/EIJ-D-17-01152

Latest news

NEW ISSUE

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

AHEAD OF PRINT

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

AHEAD OF PRINT

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

AHEAD OF PRINT

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.